secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001104659-21-134399
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q3 2021 net loss widens to $17.9M; cash position $235.3M
-----------------------------------------------------------------

- Net loss of $17.9M for Q3 2021 vs $16.4M in Q3 2020, driven by higher R&D and G&A costs.
- Cash, cash equivalents and marketable securities $235.3M at Sep 30, 2021, down $48.1M from Dec 31, 2020.
- R&D expenses $13.6M (up from $12.7M) and G&A $4.9M (up from $4.7M) year-over-year.
- Appointed Ellen G. Feigal and Anne Borgman to Board of Directors; added three new Scientific Advisory Board members.
- Cash runway expected to fund operations into second half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921134399/0001104659-21-134399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465921134399/tm2131564d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-134399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer